Profilaksa DVT kod velikih ortopedskih operacija - Depol ...

More documents

Recommendations

Info

80 2 st INTERNATIONAL CONFERENCE ON REGENERATIVE ORTHOPAEDICS DNA DEMETHYLATING AGENT 5-AZACYTIDINE NEGATIVELY AFFECTS PROLIFERATION OF MAMMALIAN LIMB BUD CELLS IN AN ORGAN-CULTURE SYSTEM Vedrana Mužić, University of Zagreb, School of Medicine, Department of Biology, Department of Rehabilitation and Orthopaedic Devices, Clinical Hospital Centre Zagreb, Zagreb, Croatia Gordana Jurić-Lekić, University of Zagreb, School of Medicine, Departmentof Histology and Embryology Zagreb, Zagreb, Croatia Marta Himelreich, University of Zagreb, School of Medicine, Department of Histology and Embryology Zagreb, Croatia Željka Majić, University of Zagreb, School of Medicine, Department of Biology, Zagreb, Croatia Nino Sinčić, University of Zagreb, School of Medicine, Department of Biology Zagreb, Croatia Ana Katušić, University of Zagreb, School of Medicine, Department of Biology Zagreb, Croatia Maja Vlahović, University of Zagreb, School of Medicine, Department of Biology Zagreb, Croatia Ljiljana Šerman, University of Zagreb, School of Medicine, Department of Biology, Zagreb, Croatia Jelena Lončarević, University of Zagreb, School of Medicine, Departmentof Histology and Embryology, Zagreb, Croatia Floriana Bulić-Jakuš, University of Zagreb, School of Medicine, Department of Biology, Zagreb, Croatia Epigenetic drug, DNA demethylating agent 5-azacytidine (5azaC), impairs overall growth of ex vivo cultivated rat limb buds. The aim of this investigation was to assess proliferative capacity of rat limb buds cultivated with 5azaC at the single cell level. 13-days-old embryos were isolated from pregnant Fisher rat females and limb buds were microsurgically isolated under the stereomicroscope. They were cultivated in an organ-culture system at the air-liquid interface in MEM and 50% rat serum. 5-azacytidine (5mmol) was added to the culture medium. During the second week, explants were processed for immunohistochemistry on Anti-Proliferating Cell Nuclear Antigen (PCNA). PCNA positive cells were stereologically evaluated using numerical density (Nv) and results were statistically compared with Student’s t-test. In both fore-limb and hind-limb explants, either treated or controls, differentiation proceeded in comparison to 13-days-old limb buds. PCNA was expressed in some cells of the cartilage, stratified squamous epithelium and mesenchyme. Nv values for PCNA were significantly lower (p
20 - 22 September 2012, Opatija, Croatia RESULTS OF 2 ND GENERATION AUTOLOGOUS CHONDROCYTE IMPLANTATION IN THE MANAGEMENT OF FOCAL ARTICULAR CARTILAGE DEFECTS Rutul Gandhi, B J Medical College, Ahmedabad, India BACKGROUND: Autologous Chondrocyte Implantation is the most widely used cell based surgical procedure for the repair of articular cartilage defects. Both short term and long term results are reported to be good or excellent in 80 to 95 percent of cases. MRI has emerged as the procedure of choice for assessment of graft survival and cartilage maturation after ACI and for predicting outcome and directing rehabilitation. In this study we intend to assess the results of ACI in patients with focal articular defects and correlating the MRI findings with clinical outcome. MATERIALS AND METHODS: Since July 2010, 12 patients with focal articular cartilage defects grade 3 or 4 according to ICRS grading were treated with ACI. IKDC knee scores were calculated pre operatively and then at 6 months and then at 12 months. All patients completed subjective knee evaluation forms before and at 6 months and 1 year after surgery. MRI was performed post procedure at 12 weeks and then at 12 months and MOCART scoring done based on the studies. All adverse events recorded and all data analysed using appropriate tests. OBSERVATIONS AND RESULTS: 1. Subjective evaluation and functional status: There was a significant improvement in the patients subjective knee score from a mean of 40.5 points to 88.5 points at the end of 12 months. Before operation only 25% graded their knee function as level I or II which significantly improved to 75% having grade I or II at 12 months 2. IKDC clinical score: Before operation 75% were classified as A or B using the IKDC objective scoring criteria, which deteriorated to only 33.3% rated as A or B at 6 months. However again at 12 months there was a significant clinical recovery with 83.3% rated as A or B. 3. MRI results and MOCART scores: The mean MOCART scores at 6 months were 80 which improved to 90 at 12 months. At 6 months 50% lesions showed normal or nearly normal scores which improved to 83.3% lesions been graded as normal or nearly normal at 12 months. CONCLUSIONS: ACI has emerged as one of the leading treatment strategies in management of focal articular defects. These superior results are attributed to the capacity of ACI to produce hyaline articular cartilage. We recommend 12 months MRI to be a reasonable non invasive means of assessing the maturation of the graft after ACI. Poster 81
Page 1 and 2:
FINAL PROGRAM BOOK OF ABSTRACTS ORG
Page 3 and 4:
CONTENTS 20 - 22 September 2012, Op
Page 5 and 6:
Organized by: Croatian Academy of S
Page 7 and 8:
CONFERENCE PROGRAMME: September 21
Page 9 and 10:
17:15 - 17:25 Discussion 20:00 Soci
Page 11 and 12:
20 - 22 September 2012, Opatija, Cr
Page 13 and 14:
BOOK OF ABSTRACTS 20 - 22 September
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
STEM CELLS FOR THE CURIOUS Stanimir
Page 27 and 28:
Page 29 and 30: 20 - 22 September 2012, Opatija, Cr
Page 39 and 40: ARTHRITIS GENE THERAPY Christopher
Page 47: 20 - 22 September 2012, Opatija, Cr
Page 50 and 51: 50 2 st INTERNATIONAL CONFERENCE ON
Page 78 and 79: fondaparinuks Profilaksa DVT kod ve
Page 94: 94 2 st INTERNATIONAL CONFERENCE ON
show all

Profilaksa DVT kod velikih ortopedskih operacija - Depol ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?